Cargando…

CONSORT 2010 statement: extension to randomised pilot and feasibility trials

The Consolidated Standards of Reporting Trials (CONSORT) statement is a guideline designed to improve the transparency and quality of the reporting of randomised controlled trials (RCTs). In this article we present an extension to that statement for randomised pilot and feasibility trials conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Eldridge, Sandra M., Chan, Claire L., Campbell, Michael J., Bond, Christine M., Hopewell, Sally, Thabane, Lehana, Lancaster, Gillian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154046/
https://www.ncbi.nlm.nih.gov/pubmed/27965879
http://dx.doi.org/10.1186/s40814-016-0105-8
_version_ 1782474805769928704
author Eldridge, Sandra M.
Chan, Claire L.
Campbell, Michael J.
Bond, Christine M.
Hopewell, Sally
Thabane, Lehana
Lancaster, Gillian A.
author_facet Eldridge, Sandra M.
Chan, Claire L.
Campbell, Michael J.
Bond, Christine M.
Hopewell, Sally
Thabane, Lehana
Lancaster, Gillian A.
author_sort Eldridge, Sandra M.
collection PubMed
description The Consolidated Standards of Reporting Trials (CONSORT) statement is a guideline designed to improve the transparency and quality of the reporting of randomised controlled trials (RCTs). In this article we present an extension to that statement for randomised pilot and feasibility trials conducted in advance of a future definitive RCT. The checklist applies to any randomised study in which a future definitive RCT, or part of it, is conducted on a smaller scale, regardless of its design (eg, cluster, factorial, crossover) or the terms used by authors to describe the study (eg, pilot, feasibility, trial, study). The extension does not directly apply to internal pilot studies built into the design of a main trial, non-randomised pilot and feasibility studies, or phase II studies, but these studies all have some similarities to randomised pilot and feasibility studies and so many of the principles might also apply. The development of the extension was motivated by the growing number of studies described as feasibility or pilot studies and by research that has identified weaknesses in their reporting and conduct. We followed recommended good practice to develop the extension, including carrying out a Delphi survey, holding a consensus meeting and research team meetings, and piloting the checklist. The aims and objectives of pilot and feasibility randomised studies differ from those of other randomised trials. Consequently, although much of the information to be reported in these trials is similar to those in randomised controlled trials (RCTs) assessing effectiveness and efficacy, there are some key differences in the type of information and in the appropriate interpretation of standard CONSORT reporting items. We have retained some of the original CONSORT statement items, but most have been adapted, some removed, and new items added. The new items cover how participants were identified and consent obtained; if applicable, the prespecified criteria used to judge whether or how to proceed with a future definitive RCT; if relevant, other important unintended consequences; implications for progression from pilot to future definitive RCT, including any proposed amendments; and ethical approval or approval by a research review committee confirmed with a reference number. This article includes the 26 item checklist, a separate checklist for the abstract, a template for a CONSORT flowchart for these studies, and an explanation of the changes made and supporting examples. We believe that routine use of this proposed extension to the CONSORT statement will result in improvements in the reporting of pilot trials. Editor’s note: In order to encourage its wide dissemination this article is freely accessible on the BMJ and Pilot and Feasibility Studies journal websites. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40814-016-0105-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5154046
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51540462016-12-13 CONSORT 2010 statement: extension to randomised pilot and feasibility trials Eldridge, Sandra M. Chan, Claire L. Campbell, Michael J. Bond, Christine M. Hopewell, Sally Thabane, Lehana Lancaster, Gillian A. Pilot Feasibility Stud Research The Consolidated Standards of Reporting Trials (CONSORT) statement is a guideline designed to improve the transparency and quality of the reporting of randomised controlled trials (RCTs). In this article we present an extension to that statement for randomised pilot and feasibility trials conducted in advance of a future definitive RCT. The checklist applies to any randomised study in which a future definitive RCT, or part of it, is conducted on a smaller scale, regardless of its design (eg, cluster, factorial, crossover) or the terms used by authors to describe the study (eg, pilot, feasibility, trial, study). The extension does not directly apply to internal pilot studies built into the design of a main trial, non-randomised pilot and feasibility studies, or phase II studies, but these studies all have some similarities to randomised pilot and feasibility studies and so many of the principles might also apply. The development of the extension was motivated by the growing number of studies described as feasibility or pilot studies and by research that has identified weaknesses in their reporting and conduct. We followed recommended good practice to develop the extension, including carrying out a Delphi survey, holding a consensus meeting and research team meetings, and piloting the checklist. The aims and objectives of pilot and feasibility randomised studies differ from those of other randomised trials. Consequently, although much of the information to be reported in these trials is similar to those in randomised controlled trials (RCTs) assessing effectiveness and efficacy, there are some key differences in the type of information and in the appropriate interpretation of standard CONSORT reporting items. We have retained some of the original CONSORT statement items, but most have been adapted, some removed, and new items added. The new items cover how participants were identified and consent obtained; if applicable, the prespecified criteria used to judge whether or how to proceed with a future definitive RCT; if relevant, other important unintended consequences; implications for progression from pilot to future definitive RCT, including any proposed amendments; and ethical approval or approval by a research review committee confirmed with a reference number. This article includes the 26 item checklist, a separate checklist for the abstract, a template for a CONSORT flowchart for these studies, and an explanation of the changes made and supporting examples. We believe that routine use of this proposed extension to the CONSORT statement will result in improvements in the reporting of pilot trials. Editor’s note: In order to encourage its wide dissemination this article is freely accessible on the BMJ and Pilot and Feasibility Studies journal websites. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40814-016-0105-8) contains supplementary material, which is available to authorized users. BioMed Central 2016-10-21 /pmc/articles/PMC5154046/ /pubmed/27965879 http://dx.doi.org/10.1186/s40814-016-0105-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Eldridge, Sandra M.
Chan, Claire L.
Campbell, Michael J.
Bond, Christine M.
Hopewell, Sally
Thabane, Lehana
Lancaster, Gillian A.
CONSORT 2010 statement: extension to randomised pilot and feasibility trials
title CONSORT 2010 statement: extension to randomised pilot and feasibility trials
title_full CONSORT 2010 statement: extension to randomised pilot and feasibility trials
title_fullStr CONSORT 2010 statement: extension to randomised pilot and feasibility trials
title_full_unstemmed CONSORT 2010 statement: extension to randomised pilot and feasibility trials
title_short CONSORT 2010 statement: extension to randomised pilot and feasibility trials
title_sort consort 2010 statement: extension to randomised pilot and feasibility trials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154046/
https://www.ncbi.nlm.nih.gov/pubmed/27965879
http://dx.doi.org/10.1186/s40814-016-0105-8
work_keys_str_mv AT eldridgesandram consort2010statementextensiontorandomisedpilotandfeasibilitytrials
AT chanclairel consort2010statementextensiontorandomisedpilotandfeasibilitytrials
AT campbellmichaelj consort2010statementextensiontorandomisedpilotandfeasibilitytrials
AT bondchristinem consort2010statementextensiontorandomisedpilotandfeasibilitytrials
AT hopewellsally consort2010statementextensiontorandomisedpilotandfeasibilitytrials
AT thabanelehana consort2010statementextensiontorandomisedpilotandfeasibilitytrials
AT lancastergilliana consort2010statementextensiontorandomisedpilotandfeasibilitytrials
AT consort2010statementextensiontorandomisedpilotandfeasibilitytrials